Cell and Gene Outsourcing

  1. Optimization-By-Design — A Critical Factor In Viral Vector Scale Up 12/14/2023

    Learn how leveraging the expertise and capabilities of an experienced partner is a key factor in optimizing AAV processes using Design of Experiment (DoE), thereby reducing variability and risk.

  2. Early Preclinical Development: A Successful Transition To cGMP Manufacturing 12/2/2024

    Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

  3. AAV Analytics: Key Considerations When Developing A Clinical Program 4/25/2024

    Finding partners with the necessary skills to optimize AAV processes is crucial for minimizing risk. Explore key considerations for advancing your therapy from concept to commercialization.

  4. Selecting Containers For Sensitive And Costly Cell & Gene Therapies

    Explore the challenges related to packaging of cell and gene therapy products and proven solutions to enable speed to market and compatibility, performance of packaging materials.

  5. Viral Vector Manufacturing: Improve Efficiency With A Platform Approach 9/25/2023

    Learn more about the platform-based scalable suspension process for LVV production and how it is impacting CGTs advancing toward commercialization.

  6. Candidate Screening And Feasibility Studies For Viral Gene Therapies

    Create a simple, modular path to cGMP manufacturing that minimizes risk. Explore a strategic approach for early-stage development and how it can propel therapies to the clinic and the market.

  7. Early Developability And Analytical Toolbox For The Production Of Multi-Chain Biotherapeutics

    In recent years, the number of biotherapeutic molecules requiring more complex assemblies has greatly increased. Typically, these multi-chain molecules are no longer compatible with platform approaches and require a more agile approach to early developability and method development.

  8. Tailored CMC Solutions That Meet Needs Of Novel Molecular Biologic Formats

    Explore an integrated drug substance/drug product CMC strategy and technical case studies that provide insight into delivering product-specific solutions and enabling the acceleration of novel molecular formats.

  9. Expertise In Commercial Fill-Finish For More Than 30 Years 8/5/2024

    Examine how a new high-speed aseptic filling line can help bring your product to market with speed and efficiency while ensuring safety and high product quality.

  10. Optimizing Viability And Standardization For Clinical Excellence 10/2/2024

    Explore how IntegriCell™ delivers high-quality, manufacture-ready cryopreserved leukopaks, vital for consistent and reliable cell therapy production.